-
Mashup Score: 5Cardiac Complications of Radiation Therapy - 2 month(s) ago
Radiation therapy is a critical component in managing many malignancies by improving local control and survival. The benefits of radiation may come at the expense of unintended radiation injury to the surrounding normal tissues, with the heart being one of the most affected organs in thoracic radiation treatments. As cancer survivors live longer, radiation-induced cardiotoxicity (RICT) is now increasingly recognized. In this review, we highlight the spectrum and pathophysiology of RICT. We summarize contemporary recommendations for risk stratification, screening, prevention, and management of RICT. We briefly highlight novel applications for radiation to treat some cardiac conditions such as resistant arrhythmias.
Source: www.cardiology.theclinics.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 2Cardiovascular Risk in Prostate Cancer - 2 month(s) ago
Cardiovascular disease is common in patients with prostate cancer and is an important cause of death. Cardiovascular risk factors are frequent in this population and are often not addressed to thresholds recommended by cardiovascular practice guidelines. Androgen deprivation therapy (ADT) reduces muscle strength and increases adiposity, thereby increasing the risk of diabetes and hypertension, although its relationship with adverse cardiovascular events requires confirmation. Androgen receptor signaling inhibitors and CYP17A1 inhibitors may confer incremental risks of hypertension and cardiovascular events to ADT. Lower cardiovascular risk with gonadotropin-releasing hormone antagonists as compared with agonists requires prespecified randomized clinical trial confirmation,
Source: www.cardiology.theclinics.comCategories: General Medicine News, CardiologistsTweet-
Another known cancer where CVD is a top cause of death...prostate cancer. @McMasterU @DarrylLeong et al highlight the methodologic challenges in understanding and differentiating baseline CV risk from cardiotoxicity from ADT and newer tx agents. https://t.co/hnixlXOwNb 10/ 🧵 https://t.co/H2GAC5284Q
-
-
Mashup Score: 1Evolving Strategies in Cardiac Amyloidosis - 2 month(s) ago
Diagnosis and treatment of cardiac amyloidosis have rapidly evolved over the past decade by harnessing mechanisms of disease pathogenesis. Cardiac amyloidosis is caused by myocardial deposition of fibrils formed by misfolded proteins, namely transthyretin (ATTR) and immunoglobulin light chains (AL). Advances in noninvasive imaging have revolutionized diagnosis of ATTR cardiomyopathy (CM). Novel treatments for ATTR-CM utilize a range of therapeutic techniques, including protein stabilizers, interfering RNA, gene editing, and monoclonal antibodies. AL-CM, primarily driven by plasma cell dyscrasias, requires treatment with chemotherapy and consideration for autologous stem cell transplant. These incredible advances aim to improve patient outcomes in cardiac amyloidosis.
Source: www.cardiology.theclinics.comCategories: General Medicine News, CardiologistsTweet-
It is certainly an exciting time for amyloid, with emerging tx coming through the pipeline our @UCLAHealth #bruinhearts @A_SteinMerlob #rachelswier et al highlight these exciting advances and a clinical guide to dx & tx! https://t.co/QRPu8YRbIr 11/ 🧵 https://t.co/AmRXYhkBnO
-
-
Mashup Score: 4Arrhythmia Challenges in Cardio-Oncology - 2 month(s) ago
Cardiovascular disease and cancer are the leading cause of mortality in the United States. In 2021, there were 695,547 and 605,213 deaths due to heart disease and cancer, respectively. With novel oncologic and cardiac therapies, survival has improved leading to increased life-expectancy albeit with chronic illness burden. Arrhythmia management in patients with cancer, whether active or in remission, can be quite challenging. In this review, we will discuss high-risk oncological therapies, prevention, and management of Atrial fibrillation, Ventricular Arrhythmias, and Bradyarrhythmias.
Source: www.cardiology.theclinics.comCategories: General Medicine News, CardiologistsTweet-
Arrhythmia Challenges in #cardioonc--a problem we all see, but still an elusive clinical issue. @OSUWexMed @AdamPotterMDPhD @SnehaSharmaDO #jonathanwright review the whole spectrum of arrhythmias & management in cancer & 💊 interactions to watch for! https://t.co/2h0TDxDBzQ 7/🧵 https://t.co/9bPs6FjArH
-
-
Mashup Score: 3Ischemic Heart Disease in the Cancer Population - 2 month(s) ago
Patients with cancer are at increased risk of ischemic heart disease (IHD). The increased risk of IHD in these patients is due to the interaction of shared risk factors, cancer type and stage, and immuno/chemotherapy and radiotherapy regimens. Management of IHD in cancer patients is challenging, due to atypical presentation, increased thrombotic and bleeding risk, and worse outcomes compared to patients without cancer. In this review, we will discuss the trends, outcomes, epidemiology and challenges in the diagnosis and treatment of IHD among cancer patients.
Source: www.cardiology.theclinics.comCategories: General Medicine News, CardiologistsTweet-
Good ol' fashioned coronary artery disease--a rising cause of morbidity & mortality in a ⏫cancer population. @zahra_raisi #dorinacondurache @arjunkg @mmamas1973 review the epidemiology of CAD/ACS, & how to close the gaps in tx & dx in #cardioonc https://t.co/ruOvtW0bGU 8/🧵 https://t.co/R7WGc9ynM4
-
-
Mashup Score: 7Cardiovascular Health in Breast Cancer - 2 month(s) ago
Improved screening and treatment have increased breast cancer survival rates, with over 7.8 million women surviving 5 years post-diagnosis globally. However, survivors face heightened cardiovascular morbidity and mortality due to cancer treatment and patient related risk factors. Cardio-oncology has emerged as a discipline to manage cardiovascular health in patients throughout and following cancer treatment. This review focuses on strategies to optimize cardiovascular health in breast cancer survivors, aligning with ASCO’s survivorship principles. Key strategies include risk stratification, primary prevention, lifestyle interventions, pharmacologic management, appropriate cardiovascular monitoring, and tailored exercise programs. Effective cardio-oncology care hinges on collaboration between specialists and patients, underscoring the significance of shared-care models and telemedicine options in survivorship management.
Source: www.cardiology.theclinics.comCategories: General Medicine News, CardiologistsTweet-
Breast cancer has come a long way, with many women having curable disease states and overall excellent survival rates. However, the risk of cardiotoxicity and CV disease remains, w/ excellent review by @sdent_cardioonc @coraleakappel et al https://t.co/jqR5d8g3qb 9/ 🧵 https://t.co/5P9PM07XMR
-
-
Mashup Score: 6
Adults with congenital heart disease make up most patients with congenital heart disease vastly surpassing the pediatric patients largely because of significant improvements in the medical, interventional, and surgical approaches. An increasing body of evidence highlights the impact of noncardiac morbidity and mortality in these patients. Malignancy is a known major cause of death in adult patients with congenital heart disease. The causes are multifactorial, including genetics, radiation, delayed age-appropriate screening, anatomy variations, and thymectomy. This article provides an overview of the specific risk factors and how health care providers and patient education can mitigate some of these risk factors.
Source: www.cardiology.theclinics.comCategories: General Medicine News, CardiologistsTweet-
Cancer rates are ⏫ In the ⏫ #ACHD population...esp at younger ages. This unique population, through their unusual CV pathophysiology & unknown cardiotoxicity profile deserve further study, as highlighted by @UCLAHealth #gentianlluri @PVenkateshMD https://t.co/RYuNPNfiZ6 5/🧵 https://t.co/Tvfny5uZ4k
-
-
Mashup Score: 3Classes of Antineoplastic Agents Associated with Increased Risk of Cancer Therapy-associated Hypertension and Management Strategies - 2 month(s) ago
Hypertension (HTN) has been found to be the most common comorbidity in patients with cancer. In addition to increased prevalence of baseline HTN, patients with cancer may be at increased risk of HTN as a short-term or long-term adverse event from cancer therapy. Different classes of cancer therapies have been implicated in the development of HTN, including inhibitors of vascular endothelial growth factor (VEGF), Bruton tyrosine kinase inhibitors, proteasome inhibitors, androgen deprivation therapy, and others. While some of these drugs may lead to increases in blood pressure through on-target effects (eg, with VEGF inhibition), others may be associated with HTN from off-target mechanisms that are not always well understood.
Source: www.cardiology.theclinics.comCategories: General Medicine News, CardiologistsTweet-
Want to know how help manage unique causes of HTN in #cardioonc? @StanfordCVI #hodasayegh @Ron_Witteles @HanZhuMD @SWaliany et al provide a great overview on HTN in cancer, as well as unusual drug classes that can exacerbate/cause HTN (ie VEGFi!) https://t.co/fa9KhrEtHr 6/🧵 https://t.co/dJKMyPRII2
-
-
Mashup Score: 6
Clonal hematopoiesis of indeterminate potential (CHIP) is an age-related phenomenon in which somatic mutations lead to clonal expansion of hematopoietic stem cells without the development of hematologic abnormalities. A growing body of literature demonstrates an association between CHIP and cardiovascular disease. This pathophysiology demonstrates a novel connection between global inflammation and cardiovascular morbidity. While there is limited consensus addressing the cardiovascular care of these patients, risk factor optimization and disease surveillance are advisable. Investigation into possible therapies is ongoing and provides promise for the treatment of inflammation contributing to cardiovascular disease in patients with and without CHIP.
Source: www.cardiology.theclinics.comCategories: General Medicine News, CardiologistsTweet-
...@uclaCVfellows STAR #bruinhearts fellow @MichaelR21 @AlexBickMDPhD provide this great overview of the increasing potential and role of clonal hematopoiesis of indeterminate potential & itsassociations w/ CV disease. #CHIP https://t.co/KeN6MwdUdM 4/ 🧵 https://t.co/FEgJNxcxuu
-
-
Mashup Score: 11Cardiovascular Risk Assessment and Prevention in Cardio-Oncology - 2 month(s) ago
This review goes beyond traditional approaches in cardio-oncology, highlighting often-neglected factors impacting patient care. Social determinants, environment, health care access, and gut microbiome significantly influence patient outcomes. Powerful tools like multi-omics and wearable technologies offer deeper insights into real-world experiences. The future lies in integrating these advancements with established practices to achieve precision cardio-oncology care. By crafting tailored therapies and continuously updating comprehensive management plans based on real-time data, we can unlock the full potential of personalized care for all patients.
Source: www.cardiology.theclinics.comCategories: General Medicine News, CardiologistsTweet-
Next, #OmarMakram @NainPriyanshu @avirupguha et al discuss the broad challenges--and opportunities--in understanding the complex interplay of CV risk assessment and prevention in #cardioonc...beyond traditional risk factors https://t.co/eTK4qMWcNj 3/🧵 https://t.co/4Qf3kqylLA
-
One of the more dynamic fields in cancer tx is the evolution of radiation therapy--as well as cardiotoxicity @joshmitchellmd @carmenbergom @RajaZaghlol et al provide this excellent review of past, present and future avenues radiation CV toxicity https://t.co/vnlbINulU7 13/ 🧵 https://t.co/HOHOHS0LIT